Clinical reference Biomarker Directory
Back to directory

GPT

Established

GPT/ALT is a liver-specific enzyme marker, central to MASLD/MASH diagnosis under the 2023-renamed disease framework.

Also known as ALT alanine aminotransferase GPT SGPT
In plain language

ALT is a liver enzyme test whose disease name recently changed — "fatty liver disease" is now officially called MASLD to better reflect its connection to metabolic health. Also worth knowing: many people with a lab-"normal" ALT may still have relevant liver fat buildup, since typical lab reference ranges run higher than what's truly healthy.

Biomarker & context

GPT (glutamate pyruvate transaminase) is the gene symbol for alanine aminotransferase (ALT), a liver enzyme more specific to hepatocellular injury than AST since it is found predominantly in the liver rather than multiple tissues.

What it indicates

Elevated ALT is a sensitive marker of liver cell injury, commonly from viral hepatitis, alcohol use, medications, or metabolic dysfunction-associated steatotic liver disease (MASLD, formerly called NAFLD).

Diagnosis & clinical testing

In June 2023, NAFLD was formally renamed MASLD (metabolic dysfunction-associated steatotic liver disease) by a multi-society consensus, specifically to remove stigmatizing language and tie the diagnosis to actual metabolic risk factors rather than just excluding alcohol; this is now the current terminology across AASLD/EASL guidelines. Standard lab-reported "normal" ALT ranges are also higher than what's actually normal for liver health — true normal is lower (29-33 U/L in men, 19-25 U/L in women per AASLD).

Guiding treatment

ALT is used both diagnostically and as a monitoring biomarker for treatment response in pediatric and adult fatty liver disease trials; persistently elevated ALT despite lifestyle intervention may prompt escalation to pharmacologic MASLD/MASH therapy or further fibrosis workup via FIB-4.

Clinical significance

The June 2023 NAFLD-to-MASLD nomenclature change reflects a major, current shift in how fatty liver disease is classified.

References
  1. AASLD. (2023). Steatotic-What? Changes in Fatty Liver Nomenclature.
  2. PMC. (2023). Precipitous changes in nomenclature and definitions—NAFLD becomes SLD.